Angiogenesis and Vascular Endothelial Growth Factors in Intraocular Tumors

Missotten, Guy S.; Schlingemann, Reinier O.; Jager, Martine J.

doi:10.1159/000320015

Cited by 10 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One possibility for targeted therapy includes the use of monoclonal antibodies able to recognize molecules of the surface of tumour cells. This approach was reported for other ocular tumours (Missotten et al 2010) and other paediatric neuroectodermic tumours such as neuroblastoma. In neuroblastoma, passive immunotherapy with monoclonal antibodies directed to the ganglioside GD2, present in the cell surface, is used for the treatment of disseminated disease (Seeger 2011;Cheung et al 2012;Ahmed & Cheung 2014), but as disseminated disease is uncommon in developed countries, there is little experience in retinoblastoma.…”

Section: Introductionmentioning

confidence: 85%

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Torbidoni

Scursoni

Camarero

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Introduction: The identification of molecules expressed selectively on the surface of retinoblastoma cells would allow applying targeted therapies. The Ganglioside, N-Glycolyl-GM3 (NeuGc-GM3), is an attractive candidate, as it has been detected in other paediatric neuroectodermic tumours, and it is not expressed in human normal tissues. The 14F7 antibody recognizes specifically the ganglioside NeuGc-GM3. Purpose: To characterize the expression of NeuGc-GM3 in retinoblastoma cell lines and in retinoblastoma tumours using the 14F7 monoclonal antibody. Methods: We studied WERI-Rb1 and Y79 cell lines, 24 retinoblastoma primary tumours from unilateral and bilateral cases and two bone marrow biopsies from metastatic retinoblastoma. Tumours were classified into three groups: non-invasive (n = 13), invasive (n = 9) and metastatic (n = 2). Three eyes enucleated because of non-tumoural conditions were used as controls. Cell lines and tumour sections were studied by immunohistochemistry using the 14F7 antibody. NeuGc-GM3 expression was evaluated by analysing the percentage of positive tumoural cells and the staining intensity. These parameters were analysed comparatively among the three groups. Results: Both retinoblastoma cell lines showed immunoreactivity to NeuGc-GM3 but WERI-Rb1 presented higher intensity than Y79. All the tumours studied showed strong immunoreactivity to NeuGc-GM3 with no significant differences among groups. In both bone marrow specimens, NeuGc-GM3 immunoreactivity was observed in retinoblastoma cells. In bilaterally enucleated cases, NeuGc-GM3 immunoreactivity was not altered before and after chemotherapy. Non-tumoural retinas were negative. Conclusions: NeuGc-GM3 is highly expressed in retinoblastoma cell lines, tumours and metastatic cells to the bone marrow, and it is not detectable in control eyes. There were no significant differences in the immunoreactivity to 14F7 among tumours from different disease stages. Its immunoreactivity did not change after chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 85%

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Torbidoni

Scursoni

Camarero

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…26 VEGF is both a vascular growth factor and a vascular permeability factor, overexpressed in most solid tumors as well as in uveal melanoma. 27 To the best of our knowledge, there are no data on corticosteroids and few data on anti-VEGF's role in the treatment of uveal melanoma-associated exudative retinal detachment. Newman and associates described, in a pilot study, that systemic bevacizumab was associated with resolution of choroidal melanoma-related exudative retinal detachment as well as transient systemic side effects.…”

Section: Methodsmentioning

confidence: 99%

Intravitreal Triamcinolone Versus Intravitreal Bevacizumab in the Treatment of Exudative Retinal Detachment Secondary to Posterior Uveal Melanoma

Parrozzani¹,

Pilotto²,

Dario³

et al. 2013

American Journal of Ophthalmology

View full text Add to dashboard Cite

“…Compared with other angiogenic factors, several studies have demonstrated that vascular endothelial growth factor (VEGF) and its receptors (VEGFR) perform central roles in a variety of cancers. For intraocular tumors, intraocular VEGF levels were increased in the patients of uveal melanoma and retinoblastoma ( 13 , 14 ). Based on these findings, a variety of anti-angiogenic drugs, including anti-VEGF antibodies such as bevacizumab and VEGF-receptor kinase inhibitors, have been developed and approved for the treatment of several types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an inï¿½vitro and inï¿½vivo model

et al. 2017

View full text Add to dashboard Cite

Retinoblastoma is the most common type of malignant intraocular tumor in children, and angiogenesis is required for tumor growth and expansion. The present study investigated whether use of the vascular endothelial growth factor inhibitor antibody bevacizumab can increase the inhibitory effect of carboplatin on human retinoblastoma Y79 cells. This was investigated using in vitro and in vivo models. Cell proliferation was assayed using a Cell Counting Kit-8 assay, which tested different concentrations of carboplatin in combination with bevacizumab. Cell apoptosis and cell cycle were analyzed using flow cytometry. Protein levels of related signaling pathway molecules were determined by western blotting. The present study used an intravitreal retinoblastoma mouse model for the in vivo study (n=40). Tumors were analyzed histologically. The present study revealed that combining bevacizumab and carboplatin in an in vitro culture of Y79 cells led to a higher inhibition of cellular proliferation than carboplatin alone (P<0.05). The drug combination caused increased apoptosis, and a greater inhibition of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways. This combination also effectively inhibited tumor growth in vivo (P<0.05). These results demonstrate that a combination of carboplatin and bevacizumab results in a greater antitumor effect in advanced human retinoblastoma in vitro and in vivo by inhibiting the PI3K/Akt and MAPK/ERK pathways.

show abstract

Angiogenesis and Vascular Endothelial Growth Factors in Intraocular Tumors

Cited by 10 publications

References 48 publications

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Intravitreal Triamcinolone Versus Intravitreal Bevacizumab in the Treatment of Exudative Retinal Detachment Secondary to Posterior Uveal Melanoma

Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an inï¿½vitro and inï¿½vivo model

Contact Info

Product

Resources

About